Prothena Corporation PLCNASDAQ:PRTA
- LAST PRICE15.8800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots14.9000/ 1
- Ask / Lots17.4500/ 10
- Open / Previous Close--- / 15.8800
- Day Range---
- 52 Week Range
- Volume83
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PRTA |
|---|---|---|
| 09:32 ET | 3772 | 15.81 |
| 09:33 ET | 500 | 15.98 |
| 09:35 ET | 5293 | 15.84 |
| 09:37 ET | 685 | 15.77 |
| 09:44 ET | 1767 | 15.98 |
| 09:46 ET | 500 | 15.935 |
| 09:48 ET | 100 | 15.99 |
| 09:50 ET | 200 | 15.955 |
| 09:51 ET | 300 | 15.96 |
| 09:55 ET | 181 | 16.04 |
| 10:02 ET | 200 | 15.99 |
| 10:04 ET | 100 | 16 |
| 10:06 ET | 400 | 16.037 |
| 10:08 ET | 1253 | 15.92 |
| 10:11 ET | 100 | 15.93 |
| 10:13 ET | 300 | 15.77 |
| 10:15 ET | 400 | 15.77 |
| 10:22 ET | 100 | 15.755 |
| 10:24 ET | 100 | 15.745 |
| 10:26 ET | 4003 | 15.53 |
| 10:27 ET | 300 | 15.46 |
| 10:29 ET | 300 | 15.49 |
| 10:31 ET | 300 | 15.43 |
| 10:36 ET | 544 | 15.46 |
| 10:38 ET | 300 | 15.46 |
| 10:40 ET | 600 | 15.505 |
| 10:42 ET | 1288 | 15.5 |
| 10:44 ET | 600 | 15.5 |
| 10:45 ET | 597 | 15.49 |
| 10:51 ET | 100 | 15.495 |
| 10:54 ET | 137 | 15.506231 |
| 10:56 ET | 600 | 15.5 |
| 10:58 ET | 1200 | 15.5 |
| 11:00 ET | 7793 | 15.5 |
| 11:02 ET | 1200 | 15.5 |
| 11:03 ET | 7062 | 15.5 |
| 11:05 ET | 100 | 15.5 |
| 11:07 ET | 500 | 15.5 |
| 11:09 ET | 9499 | 15.64 |
| 11:12 ET | 200 | 15.66 |
| 11:14 ET | 700 | 15.67 |
| 11:21 ET | 100 | 15.66 |
| 11:25 ET | 1400 | 15.68 |
| 11:27 ET | 578 | 15.68 |
| 11:30 ET | 600 | 15.68 |
| 11:32 ET | 3394 | 15.63 |
| 11:36 ET | 999 | 15.68 |
| 11:38 ET | 100 | 15.705 |
| 11:41 ET | 700 | 15.75 |
| 11:43 ET | 426 | 15.775 |
| 11:48 ET | 695 | 15.74 |
| 11:52 ET | 100 | 15.72 |
| 11:59 ET | 100 | 15.74 |
| 12:03 ET | 350 | 15.715 |
| 12:08 ET | 496 | 15.7016 |
| 12:10 ET | 1072 | 15.65 |
| 12:15 ET | 500 | 15.76 |
| 12:19 ET | 963 | 15.79 |
| 12:21 ET | 2590 | 15.8 |
| 12:24 ET | 300 | 15.77 |
| 12:28 ET | 100 | 15.785 |
| 12:33 ET | 100 | 15.79 |
| 12:35 ET | 1200 | 15.72 |
| 12:42 ET | 1024 | 15.7207 |
| 12:46 ET | 2049 | 15.69 |
| 12:48 ET | 300 | 15.66 |
| 12:50 ET | 300 | 15.715 |
| 12:53 ET | 117 | 15.725 |
| 12:55 ET | 200 | 15.725 |
| 01:06 ET | 101 | 15.72 |
| 01:15 ET | 100 | 15.73 |
| 01:20 ET | 328 | 15.715 |
| 01:29 ET | 200 | 15.65 |
| 01:36 ET | 300 | 15.63 |
| 01:38 ET | 200 | 15.65 |
| 01:42 ET | 300 | 15.69 |
| 01:47 ET | 400 | 15.68 |
| 01:49 ET | 165 | 15.685 |
| 01:51 ET | 400 | 15.685 |
| 01:56 ET | 100 | 15.685 |
| 02:00 ET | 119 | 15.715 |
| 02:07 ET | 300 | 15.69 |
| 02:12 ET | 400 | 15.68 |
| 02:14 ET | 300 | 15.65 |
| 02:18 ET | 300 | 15.675 |
| 02:21 ET | 1080 | 15.75 |
| 02:23 ET | 2052 | 15.82 |
| 02:25 ET | 100 | 15.83 |
| 02:27 ET | 2281 | 15.84 |
| 02:30 ET | 200 | 15.92 |
| 02:32 ET | 300 | 15.92 |
| 02:34 ET | 200 | 15.91 |
| 02:38 ET | 4265 | 15.87 |
| 02:41 ET | 327 | 15.9 |
| 02:43 ET | 100 | 15.93 |
| 02:48 ET | 200 | 15.915 |
| 02:52 ET | 100 | 15.92 |
| 02:57 ET | 100 | 15.92 |
| 02:59 ET | 375 | 15.955 |
| 03:01 ET | 900 | 15.8 |
| 03:03 ET | 100 | 15.785 |
| 03:06 ET | 400 | 15.79 |
| 03:08 ET | 200 | 15.78 |
| 03:10 ET | 100 | 15.82 |
| 03:12 ET | 100 | 15.8 |
| 03:14 ET | 495 | 15.785 |
| 03:17 ET | 664 | 15.775 |
| 03:19 ET | 122 | 15.8 |
| 03:21 ET | 227 | 15.83 |
| 03:26 ET | 100 | 15.815 |
| 03:28 ET | 5402 | 15.83 |
| 03:30 ET | 300 | 15.82 |
| 03:33 ET | 1234 | 15.85 |
| 03:35 ET | 628 | 15.85 |
| 03:37 ET | 100 | 15.835 |
| 03:42 ET | 100 | 15.85 |
| 03:44 ET | 1433 | 15.84 |
| 03:46 ET | 332 | 15.85 |
| 03:48 ET | 1686 | 15.86 |
| 03:50 ET | 2239 | 15.805 |
| 03:51 ET | 2671 | 15.96 |
| 03:53 ET | 1177 | 15.94 |
| 03:55 ET | 2054 | 15.92 |
| 03:57 ET | 2696 | 15.93 |
| 04:00 ET | 62314 | 15.88 |
Nov 13, 2024
DJ Prothena Price Target Maintained With a $84.00/Share by HC Wainwright & Co., from 9:50AM ET on Wednesday Nov 13, 2024 by Dow Jones
9:50AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones*DJ Prothena 3Q Loss/Shr $1.10 >PRTA, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 5, 2024
Press Release: Prothena to Report Third Quarter 2024 Financial Results on November 12, from 4:27PM ET on Tuesday Nov 05, 2024 by Dow Jones
4:27PM ET on Tuesday Nov 05, 2024 by Dow JonesProthena to Report Third Quarter 2024 Financial Results on November 12, from 4:05PM ET on Tuesday Nov 05, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Prothena Corporation PLC | 838.3M | -6.4x | --- |
Poseida Therapeutics Inc | 914.2M | -14.7x | --- |
Zymeworks Inc | 984.9M | -9.6x | --- |
Vir Biotechnology Inc | 1.0B | -2.0x | --- |
Grail Inc | 588.7M | 0.0x | --- |
Chromadex Corp | 583.6M | 403.6x | --- |
Company Information
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Contact Information
- Headquarters
- 77 Sir John Rogersons Quay Block C, Grand Canal DocklandsDUBLIN, Ireland D02 T804
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Lars Ekman
- Chief Operating Officer, Chief Scientific Officer, Head - Research and Development
- Gene Kinney
- Chief Financial Officer, Chief Strategy Officer
- Tran Nguyen
- Chief Operating Officer
- Brandon Smith
- Chief Accounting Officer
- Karin Walker
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $838.3M |
|---|---|
Revenue (TTM) | $133.4M |
Shares Outstanding | 53.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.08 |
EPS | $-2.48 |
Book Value | $10.46 |
P/E Ratio | -6.4x |
Price/Sales (TTM) | 6.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -126.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
